Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Yarrow Bioscience, Inc.MNLO · Entity 6871 | Director | June 25, 2019 | August 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Yarrow Bioscience, Inc.
Report date June 25, 2019 · Filed August 09, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2029-06-25 | Direct | 53,423 |
Reported balance
After 2019-06-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-06-25 · Grant · Acquired 22,500 · Balance 53,423 F1: The shares subject to the option will fully vest on the one year anniversary of transaction date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will fully vest on the one year anniversary of transaction date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2019 Filed Jun 27, 2019 20:15 UTC | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-19-018355 · doc4.xml · derivative · entry 1 Ebel Ted · CIK 0001727716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,423 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of transaction date. Read SEC document |
| June 25, 2019 Filed Aug 9, 2019 01:39 UTC Amendment | Yarrow Bioscience, Inc. MNLO · Entity 6871 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000899243-19-021425 · doc4a.xml · derivative · entry 1 Ebel Ted · CIK 0001727716 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,423 Underlying: Common Stock · 22,500 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the one year anniversary of transaction date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.